JUL 09, 2019 10:33 AM PDT

Effective Treatment for Ulveal Melanoma

WRITTEN BY: Nouran Amin

Ulveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly half of these diagnoses will go on to develop metastatic uveal melanoma that will target other parts of the body—mainly the liver. Prognosis is often poor with a median survival of 17 to 20 months. However, researchers have now identified a drug combination designed to target the metastatic uveal melanoma cells in preclinical studies

Learn more about uveal melanoma:

Researchers have designed uveal melanoma cell lines that were resistant to MEK inhibitors—drugs that target the MEK protein implicated in MAPK signaling of melanoma patients—and performed proteomic analysis to examine what signaling pathways were activated during the MEK inhibitor resistance process.

“We identified a number of putative escape pathways that were upregulated following MEK inhibition, including the PI3K/AKT pathway, ROR1/2 and IGF-1R signaling,” explained Keiran Smalley, PhD, director of Moffitt’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence.

Researchers were hopeful that through the identification of critical signaling pathways, they can understand how uveal melanoma cells become resistant to treatment and then counteract with an additional drug alongside MEK inhibitors.

Findings were published in Clinical Cancer Research and reveal that histone deacetylase (HDAC) inhibitors drugs, particularly panobinostat, were most effective in targeting two critical pathways in the resistance process: AKT and YAP signaling.

“Our finding that a clinically approved pan-HDAC inhibitor was effective at simultaneously limiting YAP and AKT signaling in uveal melanoma cells suggests this could be a good candidate for future clinical development,” explained Smalley.

In mouse studies, these results indicate a successful combination treatment with HDAC panobinostat along with and the MEK inhibitor trametinib is effective at uveal melanoma tumor growth reduction.

Source: Moffitt Cancer Center

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 22, 2021
Microbiology
A Nasal Spray That Seems to Prevent the Spread of COVID-19
FEB 22, 2021
A Nasal Spray That Seems to Prevent the Spread of COVID-19
Reporting in Science, researchers have created an antiviral nasal spray that could help us get the COVID-19 pandemic und ...
FEB 24, 2021
Drug Discovery & Development
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
FEB 24, 2021
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
Researchers from the University of Rochester have found that real-time functional magnetic resonance imaging (fMRI) neur ...
MAR 15, 2021
Cell & Molecular Biology
When Sample Temperature Matters: How to Keep Your Cool in the Lab
MAR 15, 2021
When Sample Temperature Matters: How to Keep Your Cool in the Lab
Temperature control is critical to many molecular and cellular experiments, but managing sample temperature requires eit ...
MAR 16, 2021
Drug Discovery & Development
Machine Learning Speeds Up Drug Discovery
MAR 16, 2021
Machine Learning Speeds Up Drug Discovery
How do drugs work? Well, they work when they stick to their target protein. Of course, there is much more complicated pr ...
APR 01, 2021
Microbiology
Mapping the Wild Microbiome to Search for Therapeutic Agents
APR 01, 2021
Mapping the Wild Microbiome to Search for Therapeutic Agents
Many people think of bacteria as disgusting germs, but there are plenty of important bacterial species that provide us w ...
JUN 01, 2021
Immunology
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
JUN 01, 2021
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
Seasonal flu vaccines only work around 40 to 60 percent of the time, says the U.S. Centers for Disease Control and Preve ...
Loading Comments...